RGEN 📈 Repligen - Overview

Repligen Corporation is a bioprocessing technology company that specializes in developing and commercializing innovative solutions for the biological drug manufacturing process. With a global presence spanning North America, Europe, the Asia Pacific, and other international markets, the company offers a diverse range of products that cater to the needs of life sciences, biopharmaceutical, and diagnostics companies, as well as laboratory researchers and contract manufacturing organizations. Its product portfolio includes Protein A ligands, which are essential components of Protein A affinity chromatography resins, and cell culture growth factor products that support the growth and development of cells in biologic drug manufacturing processes.

The company's chromatography products are designed to facilitate the purification of biologics, and include OPUS pre-packed chromatography columns, which are used in large-scale biologic drug manufacturing, as well as smaller-scale columns that are used in high-throughput process development screening, viral clearance validation studies, and scale-down validation of chromatography processes. Additionally, Repligen offers ELISA test kits and chromatography resins under the CaptivA brand, which provide a range of options for biologic drug manufacturers to optimize their purification processes. Its filtration products, such as XCell Alternating Tangential Flow systems, TangenX flat sheet cassettes, KrosFlo tangential flow filtration and tangential flow depth filtration systems, and Spectra/Por laboratory and process dialysis products, are used in various stages of biologic drug manufacturing, from upstream perfusion and cell culture processing to downstream biologic drug concentration, buffer exchange, and formulation processes.

Repligen also provides process analytics products, including slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands, which enable biologic drug manufacturers to monitor and control their processes in real-time. The company's products are designed to work together to provide a seamless and integrated solution for biologic drug manufacturing, from cell culture and purification to formulation and filling. With a strong focus on innovation and customer support, Repligen has established itself as a trusted partner for biologic drug manufacturers worldwide. The company has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands, which are used in the purification of biologics. Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen Corporation is a leading provider of bioprocessing technologies and systems, with a web presence at https://www.repligen.com and a common stock listing on the NASDAQ exchange under the ticker symbol RGEN.

As a key player in the life sciences tools and services industry, Repligen Corporation is well-positioned to support the growing demand for biologic drugs and vaccines. With its comprehensive range of products and services, the company is able to provide biologic drug manufacturers with the tools and expertise they need to develop and commercialize new therapies. Whether it's through the development of new affinity ligands, the optimization of chromatography and filtration processes, or the provision of process analytics and monitoring systems, Repligen is committed to helping its customers bring new and innovative therapies to market. With a strong track record of innovation and customer support, Repligen Corporation is a trusted partner for biologic drug manufacturers worldwide, and is poised for continued growth and success in the years to come.